Boston Scientific (BSX) Citi Annual Global Healthcare Conference 2025 summary

Growth drivers and innovation focus

• Emphasis on expanding into adjacent markets and maintaining strong growth in core procedures through innovation and value creation for products and patients.

• FARAPULSE ecosystem, including FARAWAVE and OPAL mapping, is driving electrophysiology growth at twice the market rate, with rapid adoption in the US and Europe.

• Expansion of the FARAPULSE ecosystem with new products like FARAPOINT, aiming for broader procedural coverage and workflow optimization.

• WATCHMAN franchise targets 20%+ growth, with major trials (OPTION, CHAMPION) expected to expand indications and market size significantly by 2030.

• Strategic investments in AI, imaging, and new device platforms to support leadership across cardiovascular segments.

Market penetration and competitive landscape

• US market for PFA reached over 50% penetration quickly due to broad applicability; Europe and Asia are progressing at different rates based on approvals.

• Approval of persistent AF indications and new products will accelerate further penetration of the FARAPULSE ecosystem.

• Competitive landscape in cardiology remains intense, but differentiated technology and ecosystem integration are seen as key advantages.

• Lessons from Europe highlight the unique versatility of FARAWAVE compared to competitors.

Product pipeline and clinical milestones

• Seismic IVL device for coronary therapies is in clinical trials, with data expected in 2026 and commercial launch targeted for 2027.

• Renal denervation device, acquired through VC investment, leverages ultrasound for ease of use and broader applicability in hypertension treatment.

• CRM portfolio undergoing a full refresh, with new conduction system pacing and leadless platforms nearing approval to restore market growth.

• Ongoing and upcoming clinical trials, such as CHAMPION for WATCHMAN, are expected to drive label expansion and market adoption.